Standardization of chronic hepatitis C treatment by using liaison critical pathway for the pegylated interferon and ribavirin combination therapy

概要

論文の詳細を見る
Recently numbers of chronic hepatitis C patients, treated with interferon, have been increasing. This fact in mind it becomes more and more important to predict the medical outcome, to decide early on the necessity of continuation or discontinuation of the treatment and to detect complications. In many cases it is impossible to introduce and maintain treatment while observing patients in general medical institutes or clinics alone, a liaison between those and liver diseases specialized institutes is therefore recommended. A questionnaire survey inquiring about problematic issues in regard to chronic hepatitis C diagnosis and treatment showed a demand for cooperation between the Kumamoto Medical Center and related facilities. Thus a liaison critical pathway for a combination therapy of pegylated interferon and ribavirin, which is mostly used in chronic hepatitis C treatment, was drawn up and implemented in April 2008. At the same time both national and local governmental financial support plans for interferon therapy have just been introduced. This study was based on the liaison between designated institutes and practice medical institutes and it now plays an important role in the regional chronic hepatitis C management.
特定非営利活動法人日本医療マネジメント学会の論文